ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO018

Advancing Urine-Based Cell Studies: Introducing the Cell Catcher Device

Session Information

Category: Bioengineering

  • 400 Bioengineering


  • Nazmutdinova, Katia, University College London, London, United Kingdom
  • Long, David A., University College London, London, United Kingdom
  • Walsh, Stephen B., University College London, London, United Kingdom

Urine-derived cells have gained prominence as a valuable tool for biomedical research and clinical applications due to their non-invasive and repeatable acquisition from patients, in contrast to invasive biopsies. However, the full potential of urine-derived cells remains untapped, due to lack of standardised protocols and reliance on lab-based centrifugation within 4 hours. This study aims to address these limitations by evaluating a novel filtration-based Cell Catcher device, and comparing its efficiency to centrifugation.


We obtained urine from 18 adults attending a tubulopathy clinic and directly compared the effectiveness of viable cell isolation using either Cell Catcher or centrifugation by using paired analysis.


The results demonstrate that the Cell Catcher device significantly improves the chances of obtaining viable cells, with a 28% increase compared to centrifugation. Furthermore, the device enhances the yield of primary renal cells capable of attachment and proliferation, with a twofold increase compared to conventional methods. The cultured cells showed heterogeneity in terms of cell morphology and expression of renal markers. In all samples, we detected expression of WT1 and ENPEP suggestive of podocyte and proximal tubule cells. Some samples were also positive for NPHS2, but not NPHS1, AQP3, UMOD or UPK3A.


This innovation in urine processing methods has the potential to revolutionize urine-based cell studies and unlock the vast potential of urine as a non-invasive source of patient-specific cells. Further refinements and investigations are warranted to explore the device's compatibility with different cell types and its potential applications in nephrology, regenerative medicine, and urological cancers.


  • Other NIH Support – Encelo Laboratories Limited